Medicine
Visudyne 15 mg powder for injection
Visudyne 15 mg powder for injection is a prescription medicine containing Verteporfin for intravenous use, marketed by Bausch Health, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store VISUDYNE at controlled room temperature between 20°C to 25°C (68°F to…
Key facts
- Active ingredient (INN)
- Verteporfin
- Brand
- Visudyne
- Strength
- 15 mg
- Dosage form
- Powder for injection
- Route
- Intravenous
- Packs
- 1 injection
- Marketing authorisation holder
- Bausch Health
- Manufacturers
- Bausch HealthBausch & Lomb
- Origin register
- US FDA, United States
- Storage
- Store VISUDYNE at controlled room temperature between 20°C to 25°C (68°F to 77°F). Protect from light. Any exposed person must be protected from bright light.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- S01LA01 Verteporfin
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 12 April 2000
- Identifiers
- RxCUI 313595, 351914DailyMed set ID 2f0a34ce-3c57-4ac8-b28e-512be807272f, 952f4c80-50b1-4308-9ee6-311ffefb13dfNDC 24208-560, 0187-5600Application NDA021119
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 injection, powder, lyophilized, for solution in 1 carton | 0187-5600-15 | Bausch Health | 12 April 2000 |
| 1 injection, powder, lyophilized, for solution in 1 carton | 24208-560-15 | Bausch & Lomb | 27 February 2023 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Verteporfin is a photoenhancer indicated for the treatment of patients with predominantly classic subfoveal choroidal neovascularization (CNV) due to age-related macular degeneration (AMD), pathologic myopia or presumed ocular histoplasmosis. MedsAcross supplies Verteporfin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about VerteporfinFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Visudyne prescribing information (Bausch Health) · U.S. National Library of Medicine, DailyMed
- Visudyne: European public assessment report (EPAR) · European Medicines Agency
Need Visudyne 15 mg powder for injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.